nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.17650/2311-1267-2018-5-2-32-39nodgo-381Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSТерапия внутривенными иммуноглобулинами в детской гематологии-онкологии и при трансплантации гемопоэтических стволовых клетокTherapy with intravenous immunoglobulins in pediatric hematology-oncology and transplantation of hematopoietic stem cellsКиргизовК. И.KirgizovK. I.kirill.kirgizov@fnkc.ruФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России; ФГБУ «Российская детская клиническая больница» Минздрава России;РоссияDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; Russian Children’s Clinical Hospital, Ministry of Health of RussiaRussian Federation201823042018523239Copyright © Киргизов К.И., 20182018Киргизов К.И.Kirgizov K.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/381

В обзоре литературы представлены основные сведения по использованию препаратов внутривенных иммуноглобулинов (ВВИГ) в детской гематологии-онкологии и в контексте трансплантации гемопоэтических стволовых клеток в исторической перспективе и на современном этапе. Показаны основные требования к ВВИГ, которые заключаются в использовании безопасных и качественных растворов с высоким содержанием иммуноглобулинов, которые несут минимальные риски для пациентов. Автор представляет основные показания, которые включают патогенетическую терапию аутоиммунных и вирусных заболеваний (осложнений) и заместительную терапию в целях коррекции вторичного иммунодефицита на фоне химио- и таргетной терапии.

The review of the literature presents the basic information on the use of intravenous immunoglobulins (IVIg) in pediatric hematology-oncology and in the context of hematopoietic stem cell transplantation in the historical perspective and at the present stage. The main requirements for IVIg are shown, which consist in the use of safe and quality solutions with a high content of immunoglobulins, which bear minimal risks for patients. The author presents the main indications, which include pathogenetic therapy of autoimmune and viral diseases (complications) and substitution therapy for the purpose of correction of secondary immunodeficiency against chemotherapy and targeted therapy.

внутривенные иммуноглобулиныдетигематология-онкологиятрансплантация гемопоэтических стволовых клетокбезопасностьочисткаintravenous immunoglobulinschildrenhematology-oncologyhematopoietic stem cell transplantationsafetypurificationReferencesBerger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep 2002;2(5):368–78. PMID: 12165202.Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep 2002;2(5):368–78. PMID: 12165202.Bruton O.C. Agammaglobulinemia. Pediatrics 1952;9(6):722–8. PMID: 14929630.Bruton O.C. Agammaglobulinemia. Pediatrics 1952;9(6):722–8. PMID: 14929630.Eibl M.M. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28(4):737–64, viii. doi: 10.1016/j. iac.2008.06.004.Eibl M.M. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28(4):737–64, viii. doi: 10.1016/j. iac.2008.06.004.McCue J.P., Hein R.H., Tenold R. Three generations of immunoglobulin G preparations for clinical use. Rev Infect Dis 1986; 8 Suppl 4:S374–81. PMID: 3092303.McCue J.P., Hein R.H., Tenold R. Three generations of immunoglobulin G preparations for clinical use. Rev Infect Dis 1986; 8 Suppl 4:S374–81. PMID: 3092303.Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by highdose intravenous gamma globulin. N Engl J Med 1982;306(21):1254–8. doi: 10.1056/ NEJM198205273062102.Fehr J., Hofmann V., Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by highdose intravenous gamma globulin. N Engl J Med 1982;306(21):1254–8. doi: 10.1056/ NEJM198205273062102.Imbach P., Barandun S., Baumgartner C. et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981;36(1):81–6. PMID: 6785258.Imbach P., Barandun S., Baumgartner C. et al. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv Paediatr Acta 1981;36(1):81–6. PMID: 6785258.Lusher J.M., Warrier I. Use of intravenous gamma globulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Am J Med 1987;83(4A):10–6. PMID: 3118703.Lusher J.M., Warrier I. Use of intravenous gamma globulin in children and adolescents with idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Am J Med 1987;83(4A):10–6. PMID: 3118703.Sumer T., Abumelha A., al-Mulhim I., al-Fadil M. Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gammaglobulin in childhood leukemia. Eur J Pediatr 1989;148(5):401–2. PMID: 2493376.Sumer T., Abumelha A., al-Mulhim I., al-Fadil M. Treatment of fever and neutropenia with antibiotics versus antibiotics plus intravenous gammaglobulin in childhood leukemia. Eur J Pediatr 1989;148(5):401–2. PMID: 2493376.Sullivan K.M., Kopecky K.J., Jocom J. et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323(11):705–12. doi: 10.1056/ NEJM199009133231103.Sullivan K.M., Kopecky K.J., Jocom J. et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323(11):705–12. doi: 10.1056/ NEJM199009133231103.Yap P.L. The use of intravenous immunoglobulin for the treatment of infection: an overview. J Infect 1987;15 Suppl 1:21–8. PMID: 3117897.Yap P.L. The use of intravenous immunoglobulin for the treatment of infection: an overview. J Infect 1987;15 Suppl 1:21–8. PMID: 3117897.Blanchette V., Imbach P., Andrew M. et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344(8924):703–7. PMID: 7915773.Blanchette V., Imbach P., Andrew M. et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura. Lancet 1994;344(8924):703–7. PMID: 7915773.Charles R.J., Sabo K.M., Kidd P.G., Abkowitz J.L. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996;87(11):4831–8. PMID: 8639856.Charles R.J., Sabo K.M., Kidd P.G., Abkowitz J.L. The pathophysiology of pure red cell aplasia: implications for therapy. Blood 1996;87(11):4831–8. PMID: 8639856.Kavaliotis J., Loukou I., Trachana M. et al. Outbreak of varicella in a pediatric oncology unit. Med Pediatr Oncol 1998;31(3):166–9. PMID: 9722899.Kavaliotis J., Loukou I., Trachana M. et al. Outbreak of varicella in a pediatric oncology unit. Med Pediatr Oncol 1998;31(3):166–9. PMID: 9722899.McNall R.Y., Head D.R., Pui C.H., Razzouk B.I. Parvovirus B19 infection in a child with acute lymphoblastic leukemia during induction therapy. J Pediatr Hematol Oncol 2001;23(5):309–11. PMID: 11464989.McNall R.Y., Head D.R., Pui C.H., Razzouk B.I. Parvovirus B19 infection in a child with acute lymphoblastic leukemia during induction therapy. J Pediatr Hematol Oncol 2001;23(5):309–11. PMID: 11464989.Pranzatelli M.R. Paraneoplastic syndromes: an unsolved murder. Semin Pediatr Neurol 2000;7(2):118–30. PMID: 10914413.Pranzatelli M.R. Paraneoplastic syndromes: an unsolved murder. Semin Pediatr Neurol 2000;7(2):118–30. PMID: 10914413.Mitchell W.G., Davalos-Gonzalez Y., Brumm V.L. et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002;109(1):86–98. PMID: 11773546.Mitchell W.G., Davalos-Gonzalez Y., Brumm V.L. et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics 2002;109(1):86–98. PMID: 11773546.Heath J.A., Broxson E.H. Jr, Dole M.G. et al. Epstein–Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue. J Pediatr Hematol Oncol 2002;24(2):160–3. PMID: 11998794.Heath J.A., Broxson E.H. Jr, Dole M.G. et al. Epstein–Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue. J Pediatr Hematol Oncol 2002;24(2):160–3. PMID: 11998794.Durandy A., Kaveri S.V., Kuijpers T.W. et al. Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol 2009;158 Suppl 1:2–13. doi: 10.1111/j.1365-2249.2009.04022.x.Durandy A., Kaveri S.V., Kuijpers T.W. et al. Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol 2009;158 Suppl 1:2–13. doi: 10.1111/j.1365-2249.2009.04022.x.Burks A., Sampson H., Buckley R. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinenia. Detection of IgE antibodies to IgA. N Engl J Med 1986;314(9):560–4. doi: 10.1056/NEJM198602273140907.Burks A., Sampson H., Buckley R. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinenia. Detection of IgE antibodies to IgA. N Engl J Med 1986;314(9):560–4. doi: 10.1056/NEJM198602273140907.Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38(4):275–84. doi: 10.1159/000354893.Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38(4):275–84. doi: 10.1159/000354893.Daw Z., Padmore R., Neurath D. et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48(8):1598–601. doi: 10.1111/j.1537-2995.2008.01721.x.Daw Z., Padmore R., Neurath D. et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48(8):1598–601. doi: 10.1111/j.1537-2995.2008.01721.x.Laguna P., Gołębiowska-Staroszczyk S., Trzaska M., Grabarczyk M., Matysiak M. Immunoglobulins and their use in children. Adv Clin Exp Med 2015;24(1):153–9. doi: 10.17219/acem/28626.Laguna P., Gołębiowska-Staroszczyk S., Trzaska M., Grabarczyk M., Matysiak M. Immunoglobulins and their use in children. Adv Clin Exp Med 2015;24(1):153–9. doi: 10.17219/acem/28626.Wong P.H., White K.M. Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms. Clin Rev Allergy Immunol 2016;51(3):303–14. doi: 10.1007/s12016-015-8499-2.Wong P.H., White K.M. Impact of Immunoglobulin Therapy in Pediatric Disease: a Review of Immune Mechanisms. Clin Rev Allergy Immunol 2016;51(3):303–14. doi: 10.1007/s12016-015-8499-2.Boruchov D.M., Gururangan S., Driscoll M.C., Bussel J.B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007;110(10):3526–31. doi: 10.1182/blood-2007-01-065763. 25. Масчан А.А., Ковалева Л.Г., Румянцев А.Г., Савченко В.Г. Современные методы диагностики и лечения первичной иммунной тромбоцитопении (по итогам совещания совета экспертов). СанктПетербург, май 2010 г. Вопросы гематологии, онкологии и иммунопатологии в педиатрии 2010;9(4):5–14. [Maschan A.A., Kovaleva L.G., Rumyantsev A.G., Savchenko V.G. Modern methods for diagnosis and treatment of primary immune thrombocytopenia (summing up the Expert Council meeting). St. Petersburg, May 2010. Voprosy gematologii, onkologii i immunopatologii v pediatrii = Questions of Hematology, Oncology and Immunopathology in Pediatrics 2010;9(4):5–14.Boruchov D.M., Gururangan S., Driscoll M.C., Bussel J.B. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007;110(10):3526–31. doi: 10.1182/blood-2007-01-065763. 25. Масчан А.А., Ковалева Л.Г., Румянцев А.Г., Савченко В.Г. Современные методы диагностики и лечения первичной иммунной тромбоцитопении (по итогам совещания совета экспертов). СанктПетербург, май 2010 г. Вопросы гематологии, онкологии и иммунопатологии в педиатрии 2010;9(4):5–14. [Maschan A.A., Kovaleva L.G., Rumyantsev A.G., Savchenko V.G. Modern methods for diagnosis and treatment of primary immune thrombocytopenia (summing up the Expert Council meeting). St. Petersburg, May 2010. Voprosy gematologii, onkologii i immunopatologii v pediatrii = Questions of Hematology, Oncology and Immunopathology in Pediatrics 2010;9(4):5–14.(In Russ.)].(In Russ.)].de Alarcon P.A., Matthay K.K., London W.B. et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health 2018;2(1):25–34. doi: 10.1016/S23524642(17)30130-X.de Alarcon P.A., Matthay K.K., London W.B. et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health 2018;2(1):25–34. doi: 10.1016/S23524642(17)30130-X.Raanani P., Gafter-Gvili A., Paul M. et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009;27(5):770–81. doi: 10.1200/ JCO.2008.16.8450.Raanani P., Gafter-Gvili A., Paul M. et al. Immunoglobulin prophylaxis in hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2009;27(5):770–81. doi: 10.1200/ JCO.2008.16.8450.Casulo C., Maragulia J., Zelenetz A.D. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013;13(2):106–11. doi: 10.1016/j. clml.2012.11.011.Casulo C., Maragulia J., Zelenetz A.D. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013;13(2):106–11. doi: 10.1016/j. clml.2012.11.011.Crabol Y., Terrier B., Rozenberg F. et al.; Groupe d’experts de l’Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013;56(7):968–77. doi: 10.1093/cid/ cis1046.Crabol Y., Terrier B., Rozenberg F. et al.; Groupe d’experts de l’Assistance Publique-Hôpitaux de Paris. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. Clin Infect Dis 2013;56(7):968–77. doi: 10.1093/cid/ cis1046.

The authors declare that there are no conflicts of interest present.